Full Press Release Details
Semler Reports 2016 First Quarter Financial
Improvement in Operating Expenses
Supports Goal of Profitability in 2016
PORTLAND, Ore. - April 29, 2016 - Semler
Scientific, Inc. (Nasdaq: SMLR; "Semler"), an emerging growth company that provides
technology solutions to improve the clinical effectiveness and efficiency of healthcare insurers and physician groups, today
reported financial results for the first quarter ended March 31, 2016.
"Semler reported a reduction in operating expenses and
an improvement in cash position through the issuance of promissory notes in the first quarter of 2016," said Doug Murphy-Chutorian,
M.D., chief executive officer of Semler. "We are pursuing the goals of profitability, positive cash flow from operations
and minimal shareholder dilution," he added.
In the three months ended March 31, 2016, compared to the corresponding
period of 2015, Semler had:
In the three months ended March 31, 2016, compared to three
months ended December 31, 2015, Semler had:
Semler issued promissory notes to obtain $2,200,000 of additional
capital in the first quarter of 2016. Also, WellChec , Semler's multi-test service, was not offered in the first quarter
of 2016. WellChec was responsible for both substantial revenue growth and associated start-up costs in the fourth quarter
of 2015, which impacts comparisons of both revenue and operating
expense from sequential quarterly periods. We expect that WellChec
will be active in the latter half of 2016.
FIRST QUARTER 2016 HIGHLIGHTS
The major accomplishments of 2016 to date are as follows:
In 2016, revenue from QuantaFlo is expected to continue
to grow due to an increasing number of installations, average pricing and the recurring revenue business model. We also plan to
limit WellChec business until later in the year. Because Semler does not give financial guidance, the magnitude of these
changes and progress towards such an operating plan will be reported during the quarterly earnings releases, and will depend on
our ability to continue to win customers for both QuantaFlo and WellChec .
grow our QuantaFlo and vascular testing products revenue and have reduced net
operating loss," said Dr. Murphy-Chutorian. "Our cash position has improved
and is expected to be sufficient to fund operations until achieving our goal of profitability," he added.
Notice of Conference Call
Semler will host a conference call at 11 a.m. EDT, Friday, April
29, 2016. The call will address first quarter results and will provide a business update on Semler's market outlook and strategies
for the near-term future.
The conference call may be accessed by dialing
877-359-9508 for domestic callers and 224-357-2393 for international callers. Please specify to the operator that you would
like to join the "Semler First Quarter 2016 Financial Results Call, conference ID#: 93156415" The conference call
will be archived on Semler's website at www.semlerscientific.com.
Semler Scientific, Inc.
Statements of Operations
(In thousands, except share and per share
| (Unaudited) For the three months ended March 31 | ||||||||
| 2016 | 2015 | |||||||
| Revenue | $ | 1,501 | 1,202 | |||||
| Operating expenses: | ||||||||
| Cost of revenue | 417 | 241 | ||||||
| Engineering and product development | 270 | 309 | ||||||
| Sales and marketing | 974 | 1,207 | ||||||
| General and administrative | 772 | 793 | ||||||
| Total operating expenses | 2,433 | 2,550 | ||||||
| Loss from operations | (932 | ) | (1,348 | ) | ||||
| Other expense: | (74 | ) | (24 | ) | ||||
| Net loss | $ | (1,006 | ) | $ | (1,372 | ) | ||
| Net loss per share, basic and diluted | $ | (0.20 | ) | $ | (0.29 | ) | ||
| Weighted average number of shares used in computing basic and diluted loss per share | 5,123,568 | 4,763,573 |
Semler Scientific, Inc.
Condensed Balance Sheets
(In thousands of U.S. Dollars)
| (Unaudited) As of March 31, | As of December 31, | |||||||
| 2016 | 2015 | |||||||
| Cash | $ | 1,441 | $ | 405 | ||||
| Other current assets | 731 | 1,347 | ||||||
| Noncurrent assets | 1,253 | 1,327 | ||||||
| Total assets | 3,425 | 3,079 | ||||||
| Current liabilities | 3,123 | 4,108 | ||||||
| Non-current liabilities | 1,963 | 43 | ||||||
| Stockholders' deficit | (1,661 | ) | (1,072 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 3,425 | 3,079 |
About Semler Scientific, Inc.:
Semler Scientific, Inc., is an
emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare
insurers and physician groups. Our mission is to develop, manufacture and market innovative proprietary products and services
that assist our customers in evaluating and treating chronic diseases. Our first patented and U.S. Food and Drug Administration,
or FDA, cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities to aid in the diagnosis
of peripheral arterial disease. In March 2015 we received FDA 510(k) clearance for the next generation version of this product
named QuantaFlo , which was commercially launched in August 2015. In April 2015, we launched our multi-test service offering,
WellChec , to more comprehensively evaluate patients for chronic disease. Additional information about Semler can be found
at semlerscientific.com.
Forward-Looking Statements
This press release contains "forward-looking" statements.
Such statements can be identified by, among other things, the use of forward-looking language such as the words "may,"
"will," "expect," "anticipate," "estimate," "project," "would,"
"could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions.
The forward-looking statements in this release include statements regarding achieving profitability and cash flow from operations,
as well the effects of Semler Scientific's products and services on prevention and
healthcare costs. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler
Scientific's actual results to differ materially from those discussed here, such as whether or not insurance plans and other
customers will continue to lease its vascular disease testing products or adopt WellChec , along with those statements detailed
in Semler Scientific's SEC filings, and involve assumptions, estimates, and uncertainties that reflect current internal projections,
expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future
events could differ materially from those anticipated in such statements. All forward looking statements contained in this press
release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such
statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements
unless otherwise required by law.
S.A. Noonan Communications
SOURCE: Semler Scientific, Inc.